Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has received an approval from its national medicines regulator for Ronapreve (casirivimab/imdevimab).
Having obtained exclusive commercialization rights in Japan from Roche (ROG: SIX), Chugai secured regulatory approval in July 2021 for the antibody cocktail as a treatment for infection with coronavirus.
The new approval from Japan’s Ministry of Health, Labor and Welfare (MHLW) allows high-risk individuals who have tested positive or who have been in close contact with COVID-19 patients to be treated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze